Global Exosomes Diagnostic and Therapeutic Market Set to Experience Remarkable Growth, Projected to Reach USD 211.6 Million by 2034

The global exosomes diagnostic and therapeutic market is on a promising trajectory, poised for significant expansion from USD 88.56 million in 2024 to an impressive USD 211.6 million by 2034. This robust growth is supported by a Compound Annual Growth Rate (CAGR) of 9.10% over the next decade, reflecting the rising interest and investment in exosome technology.

Exosomes, small vesicles released by cells, are increasingly recognized for their potential in both diagnostic and therapeutic applications. Their growing importance is evident as healthcare providers around the world strive to enhance accessibility and efficiency amidst rising patient numbers. This has led to a surge in the adoption of informatics-integrated solutions within laboratories, aimed at optimizing productivity and resource utilization.

Manufacturers in the exosomes market are capitalizing on these advancements by integrating healthcare solutions into their offerings. This strategic move not only supports diagnostic innovations but also significantly contributes to overall market growth. Key industry players are actively partnering with academic institutions to drive the research and development of novel non-invasive diagnostic tools, particularly for cancer detection. This collaborative effort underscores a shared commitment to advancing healthcare solutions that are both effective and patient-friendly.

“The growing investor interest in exosome technology, combined with increasing research studies exploring its applications, is expected to propel market growth,” says an analyst from Future Market Insights.

Key Insights from the Exosomes Diagnostic and Therapeutic Market Report:

  • Revenue Growth: The industry achieved a revenue of USD 23.3 million in 2018 and grew to USD 72.6 million by 2023, with a notable CAGR of 25.5%.
  • Product Segmentation: In 2023, the instruments segment held a 25% market share.
  • Application Segmentation: Diagnostics accounted for 68% of the market share in 2023.
  • Regional Outlook: The Canada market is projected to expand at a CAGR of 5% through 2034, while the United States is expected to see a CAGR of 4.5%. Germany’s market is anticipated to grow at a rate of 3.8%, with India and China in the Asia Pacific region expected to achieve CAGRs of 9.5% and 10%, respectively.

Access the Newest Reports from Get Old Source…

Competitive Landscape:

Biopharma companies are increasingly focused on creating exosome-based therapeutics for a wide range of conditions, and are addressing manufacturing needs through strategic acquisitions and partnerships. For example, in 2021, Lonza acquired the exosome manufacturing unit of Codiak BioSciences. Similarly, CDMOs such as RoosterBio and EXO Biologics are expanding their services to enhance exosome manufacturing capabilities in Europe.

Latest Developments:

  • July 2023: ExoCoBio acquired BENEV, merging their strengths to accelerate the commercialization of exosome technology globally.
  • January 2024: Aruna Bio received FDA clearance for its Lead Program AB126, marking the first exosome technology to enter human clinical trials for a neurological indication, highlighting its therapeutic potential.

Key Players:

The exosomes diagnostic and therapeutic market features prominent players including:

  • Thermo Fisher Scientific
  • NanoSomix
  • NX Pharmagen
  • Malvern Instruments
  • Capricor Therapeutic
  • Exosome Diagnostics
  • Exiqon A/S
  • System Biosciences
  • Exosome Sciences
  • Aegle Therapeutic
  • AMS Biotechnology
  • Miltenyi Biotec
  • Codiak BioSciences Inc.
  • Lonza Group (HansaBioMed Life Sciences Ltd.)
  • AcouSort AB
  • Aethlon Medical, Inc.
  • AGC Biologics
  • Anjarium Biosciences AG
  • Aruna Bio
  • Brexogen
  • Capricor Therapeutics
  • Cells for Cells
  • Ciloa
  • ConvEyXO
  • Others

Market Research Categories:

  • Products: Instruments, Software, Reagents and Kits
  • Applications: Diagnostics, Therapeutic
  • End Users: Hospitals, Cancer Institutes, Diagnostic Centers, Others
  • Geographic Markets: North America, Europe, Asia Pacific, Middle East and Africa, Latin America

The exosomes diagnostic and therapeutic market is on the brink of transformative growth, driven by technological advancements, strategic collaborations, and a heightened focus on non-invasive diagnostic technologies. With continued innovation and investment, this market is set to revolutionize healthcare delivery and improve patient outcomes worldwide.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Matched content

Editor’s pick

Express Press Release Distribution